BCL2 and B-cell chronic lymphocytic leukemia: Moreover, previously untreated CLL patients were evaluated after zanubrutinib treatment in combination with obinutuzumab and the B cell lymphoma-2 (BCL-2) inhibitor venetoclax in a recently published phase 2 clinical trial, with 89% of patients reaching undetectable minimal residual disease after a median treatment duration of only 10 months [94].